Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim

Lijing Su, Ying Wang, Junmei Wang, Yuto Mifune, Matthew D. Morin, Brian T. Jones, Eva Marie Y. Moresco, Dale L. Boger, Bruce Beutler, Hong Zhang

Research output: Contribution to journalArticle

Abstract

Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Since Diprovocim bears no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we investigated how Diprovocim interacts with TLR2/TLR1 through in vitro biophysical, structural, and computational approaches. We found that Diprovocim induced the formation of TLR2/TLR1 heterodimers as well as TLR2 homodimers in vitro. We determined the crystal structure of Diprovocim in a complex with a TLR2 ectodomain, which revealed, unexpectedly, two Diprovocim molecules bound to the ligand binding pocket formed between two TLR2 ectodomains. Extensive hydrophobic interactions and a hydrogen-bonding network between the protein and Diprovocim molecules are observed within the defined ligand binding pocket and likely underlie the high potency of Diprovocim. Our work shed first light into the activation mechanism of TLR2/TLR1 by a noncanonical agonist. The structural information obtained here may be exploited to manipulate TLR2/TLR1-dependent signaling.

Original languageEnglish (US)
Pages (from-to)2938-2949
Number of pages12
JournalJournal of Medicinal Chemistry
Volume62
Issue number6
DOIs
StatePublished - Mar 28 2019

Fingerprint

Ligands
Lipopeptides
Hydrogen Bonding
Hydrophobic and Hydrophilic Interactions
Melanoma
Vaccination
Light
Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Su, L., Wang, Y., Wang, J., Mifune, Y., Morin, M. D., Jones, B. T., ... Zhang, H. (2019). Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. Journal of Medicinal Chemistry, 62(6), 2938-2949. https://doi.org/10.1021/acs.jmedchem.8b01583

Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. / Su, Lijing; Wang, Ying; Wang, Junmei; Mifune, Yuto; Morin, Matthew D.; Jones, Brian T.; Moresco, Eva Marie Y.; Boger, Dale L.; Beutler, Bruce; Zhang, Hong.

In: Journal of Medicinal Chemistry, Vol. 62, No. 6, 28.03.2019, p. 2938-2949.

Research output: Contribution to journalArticle

Su, Lijing ; Wang, Ying ; Wang, Junmei ; Mifune, Yuto ; Morin, Matthew D. ; Jones, Brian T. ; Moresco, Eva Marie Y. ; Boger, Dale L. ; Beutler, Bruce ; Zhang, Hong. / Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 6. pp. 2938-2949.
@article{3b4404613ebc460fb22f84dd4dfcfda9,
title = "Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim",
abstract = "Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Since Diprovocim bears no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we investigated how Diprovocim interacts with TLR2/TLR1 through in vitro biophysical, structural, and computational approaches. We found that Diprovocim induced the formation of TLR2/TLR1 heterodimers as well as TLR2 homodimers in vitro. We determined the crystal structure of Diprovocim in a complex with a TLR2 ectodomain, which revealed, unexpectedly, two Diprovocim molecules bound to the ligand binding pocket formed between two TLR2 ectodomains. Extensive hydrophobic interactions and a hydrogen-bonding network between the protein and Diprovocim molecules are observed within the defined ligand binding pocket and likely underlie the high potency of Diprovocim. Our work shed first light into the activation mechanism of TLR2/TLR1 by a noncanonical agonist. The structural information obtained here may be exploited to manipulate TLR2/TLR1-dependent signaling.",
author = "Lijing Su and Ying Wang and Junmei Wang and Yuto Mifune and Morin, {Matthew D.} and Jones, {Brian T.} and Moresco, {Eva Marie Y.} and Boger, {Dale L.} and Bruce Beutler and Hong Zhang",
year = "2019",
month = "3",
day = "28",
doi = "10.1021/acs.jmedchem.8b01583",
language = "English (US)",
volume = "62",
pages = "2938--2949",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim

AU - Su, Lijing

AU - Wang, Ying

AU - Wang, Junmei

AU - Mifune, Yuto

AU - Morin, Matthew D.

AU - Jones, Brian T.

AU - Moresco, Eva Marie Y.

AU - Boger, Dale L.

AU - Beutler, Bruce

AU - Zhang, Hong

PY - 2019/3/28

Y1 - 2019/3/28

N2 - Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Since Diprovocim bears no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we investigated how Diprovocim interacts with TLR2/TLR1 through in vitro biophysical, structural, and computational approaches. We found that Diprovocim induced the formation of TLR2/TLR1 heterodimers as well as TLR2 homodimers in vitro. We determined the crystal structure of Diprovocim in a complex with a TLR2 ectodomain, which revealed, unexpectedly, two Diprovocim molecules bound to the ligand binding pocket formed between two TLR2 ectodomains. Extensive hydrophobic interactions and a hydrogen-bonding network between the protein and Diprovocim molecules are observed within the defined ligand binding pocket and likely underlie the high potency of Diprovocim. Our work shed first light into the activation mechanism of TLR2/TLR1 by a noncanonical agonist. The structural information obtained here may be exploited to manipulate TLR2/TLR1-dependent signaling.

AB - Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Since Diprovocim bears no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we investigated how Diprovocim interacts with TLR2/TLR1 through in vitro biophysical, structural, and computational approaches. We found that Diprovocim induced the formation of TLR2/TLR1 heterodimers as well as TLR2 homodimers in vitro. We determined the crystal structure of Diprovocim in a complex with a TLR2 ectodomain, which revealed, unexpectedly, two Diprovocim molecules bound to the ligand binding pocket formed between two TLR2 ectodomains. Extensive hydrophobic interactions and a hydrogen-bonding network between the protein and Diprovocim molecules are observed within the defined ligand binding pocket and likely underlie the high potency of Diprovocim. Our work shed first light into the activation mechanism of TLR2/TLR1 by a noncanonical agonist. The structural information obtained here may be exploited to manipulate TLR2/TLR1-dependent signaling.

UR - http://www.scopus.com/inward/record.url?scp=85063075876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063075876&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b01583

DO - 10.1021/acs.jmedchem.8b01583

M3 - Article

C2 - 30829478

AN - SCOPUS:85063075876

VL - 62

SP - 2938

EP - 2949

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -